Research ExplorerPublicationsFrequent expression of PD-L1 on circulating breast cancer ce...

Frequent expression of PD-L1 on circulating breast cancer cells

Standard

Frequent expression of PD-L1 on circulating breast cancer cells. / Mazel, Martine; Jacot, William; Pantel, Klaus; Bartkowiak, Kai; Topart, Delphine; Cayrefourcq, Laure; Rossille, Delphine; Maudelonde, Thierry; Fest, Thierry; Alix-Panabières, Catherine.

In: MOL ONCOL, Vol. 9, No. 9, 11.2015, p. 1773-82.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Mazel, M, Jacot, W, Pantel, K, Bartkowiak, K, Topart, D, Cayrefourcq, L, Rossille, D, Maudelonde, T, Fest, T & Alix-Panabières, C 2015, 'Frequent expression of PD-L1 on circulating breast cancer cells', MOL ONCOL, vol. 9, no. 9, pp. 1773-82. https://doi.org/10.1016/j.molonc.2015.05.009

APA

Mazel, M., Jacot, W., Pantel, K., Bartkowiak, K., Topart, D., Cayrefourcq, L., Rossille, D., Maudelonde, T., Fest, T., & Alix-Panabières, C. (2015). Frequent expression of PD-L1 on circulating breast cancer cells. MOL ONCOL, 9(9), 1773-82. https://doi.org/10.1016/j.molonc.2015.05.009

Vancouver

Mazel M, Jacot W, Pantel K, Bartkowiak K, Topart D, Cayrefourcq L et al. Frequent expression of PD-L1 on circulating breast cancer cells. MOL ONCOL. 2015 Nov;9(9):1773-82. https://doi.org/10.1016/j.molonc.2015.05.009

Bibtex

@article{9f4a0d2cf2d943d7b9ca200edd7df8d5,
title = "Frequent expression of PD-L1 on circulating breast cancer cells",
abstract = "Immune checkpoint regulators such as PD-L1 have become exciting new therapeutic targets leading to long lasting remissions in patients with advanced malignancies. However, in view of the remarkable costs and the toxicity profiles of these therapies, predictive biomarkers able to discriminate responders from non-responders are urgently needed. In the present paper, we provide evidence that PD-L1 is frequently expressed on metastatic cells circulating in the blood of hormone receptor-positive, HER2-negative breast cancer patients. We performed western blot, flow cytometry and immunocytochemical analyses to demonstrate the specificity of the PDL1 antibody used in our study and established immunoscores for PDL1 expression on single tumor cells. We then selected sixteen patients with circulating tumor cells (CTCs) using the CellSearch({\textregistered}) system and found PD-L1((+)) CTCs in 11 patients (68.8%). The fraction of PD-L1((+)) CTCs varied from 0.2 to 100% in individual patients. This is the first report demonstrating the expression of PD-L1 on CTCs. The established CTC/PD-L1 assay can be used for liquid biopsy in future clinical trials for stratification and monitoring of cancer patients undergoing immune checkpoint blockade.",
author = "Martine Mazel and William Jacot and Klaus Pantel and Kai Bartkowiak and Delphine Topart and Laure Cayrefourcq and Delphine Rossille and Thierry Maudelonde and Thierry Fest and Catherine Alix-Panabi{\`e}res",
note = "Copyright {\textcopyright} 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.",
year = "2015",
month = nov,
doi = "10.1016/j.molonc.2015.05.009",
language = "English",
volume = "9",
pages = "1773--82",
journal = "MOL ONCOL",
issn = "1574-7891",
publisher = "Elsevier",
number = "9",

}

RIS

TY - JOUR

T1 - Frequent expression of PD-L1 on circulating breast cancer cells

AU - Mazel, Martine

AU - Jacot, William

AU - Pantel, Klaus

AU - Bartkowiak, Kai

AU - Topart, Delphine

AU - Cayrefourcq, Laure

AU - Rossille, Delphine

AU - Maudelonde, Thierry

AU - Fest, Thierry

AU - Alix-Panabières, Catherine

N1 - Copyright © 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

PY - 2015/11

Y1 - 2015/11

N2 - Immune checkpoint regulators such as PD-L1 have become exciting new therapeutic targets leading to long lasting remissions in patients with advanced malignancies. However, in view of the remarkable costs and the toxicity profiles of these therapies, predictive biomarkers able to discriminate responders from non-responders are urgently needed. In the present paper, we provide evidence that PD-L1 is frequently expressed on metastatic cells circulating in the blood of hormone receptor-positive, HER2-negative breast cancer patients. We performed western blot, flow cytometry and immunocytochemical analyses to demonstrate the specificity of the PDL1 antibody used in our study and established immunoscores for PDL1 expression on single tumor cells. We then selected sixteen patients with circulating tumor cells (CTCs) using the CellSearch(®) system and found PD-L1((+)) CTCs in 11 patients (68.8%). The fraction of PD-L1((+)) CTCs varied from 0.2 to 100% in individual patients. This is the first report demonstrating the expression of PD-L1 on CTCs. The established CTC/PD-L1 assay can be used for liquid biopsy in future clinical trials for stratification and monitoring of cancer patients undergoing immune checkpoint blockade.

AB - Immune checkpoint regulators such as PD-L1 have become exciting new therapeutic targets leading to long lasting remissions in patients with advanced malignancies. However, in view of the remarkable costs and the toxicity profiles of these therapies, predictive biomarkers able to discriminate responders from non-responders are urgently needed. In the present paper, we provide evidence that PD-L1 is frequently expressed on metastatic cells circulating in the blood of hormone receptor-positive, HER2-negative breast cancer patients. We performed western blot, flow cytometry and immunocytochemical analyses to demonstrate the specificity of the PDL1 antibody used in our study and established immunoscores for PDL1 expression on single tumor cells. We then selected sixteen patients with circulating tumor cells (CTCs) using the CellSearch(®) system and found PD-L1((+)) CTCs in 11 patients (68.8%). The fraction of PD-L1((+)) CTCs varied from 0.2 to 100% in individual patients. This is the first report demonstrating the expression of PD-L1 on CTCs. The established CTC/PD-L1 assay can be used for liquid biopsy in future clinical trials for stratification and monitoring of cancer patients undergoing immune checkpoint blockade.

U2 - 10.1016/j.molonc.2015.05.009

DO - 10.1016/j.molonc.2015.05.009

M3 - SCORING: Journal article

C2 - 26093818

VL - 9

SP - 1773

EP - 1782

JO - MOL ONCOL

JF - MOL ONCOL

SN - 1574-7891

IS - 9

ER -